Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial

• In a prospective, controlled, randomised, multicentre study 252 patients with totally resected cutaneous melanoma (248 in stage II-III and 4 in stage IV) were either treated with two doses of dacarbazine (DTIC) followed by a 6-month treatment with 3 MU thrice weekly of highly purified natural interferon-alpha (n = 128; arm A) or received no adjuvant treatment (n = 124; arm B). Treatment was well tolerated. After a median follow-up of 8.5 years ITT analysis showed that the difference in survival was statistically significant with respect to melanoma-related deaths (HR = 0.65, CI = 0.46-0.97, p = 0.022) and close to significance with respect to overall survival (HR 0.71, CI 0.49-1.00, p = 0.052). The risk reduction of melanoma-associated death, calculated by Cox proportional hazards modelling, after adjusting for identified predictive variables, was almost 50% (p = 0.002). The overall efficacy of the treatment appeared to be mainly attributable to effects observed in patients with deep and/or metastasizing tumours (HR 0.60, CI 0.40-0.90, p = 0.013).

Nyckelord

Adult

Aged

Aged

80 and over

Antineoplastic Combined Chemotherapy Protocols/ therapeutic use

Chemotherapy

Adjuvant

Dacarbazine/administration & dosage

Female

Humans

Interferon-alpha/administration & dosage

Male

Melanoma/drug therapy/ mortality

Middle Aged

Neoplasm Recurrence

Local/drug therapy/mortality/secondary

Neoplasm Staging

Prospective Studies

Skin Neoplasms/drug therapy/ mortality

Survival Rate

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)